Filing summary
Entity and period mismatch: The supplied metadata identifies Newegg Commerce, Inc. and 2014 Q4, but the filing text is Dehaier Medical Systems Limited’s annual Form 20-F for the fiscal year ended December 31, 2014. The figures below summarize Dehaier, not Newegg, and are annual rather than quarterly.
Business context and reporting period
Dehaier develops and distributes medical devices in China, including proprietary equipment, products distributed for international suppliers, sleep-respiratory solutions and mobile-medicine services. Its business depends substantially on distributors and hospital procurement. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars; substantially all revenue is generated in China and denominated in RMB.
Financial performance and liquidity
| Metric (US$ unless stated) | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $11.99 million | $16.86 million |
| Gross profit / margin | $3.19 million / 26.62% | $6.41 million / 38.03% |
| Operating income (loss) | $(2.11) million | $3.51 million |
| Net income | $659,004 | $2.00 million |
| Net income attributable to Dehaier | $998,993 | $1.996 million |
| Basic and diluted EPS | $0.18 | $0.43 |
| Cash from operating activities | $4.14 million | $(200,450) |
| Cash from investing activities | $(11.20) million | $(1.13) million |
| Cash from financing activities | $6.26 million | $330,866 |
| Cash and cash equivalents at year-end | $1.73 million | $2.59 million |
| Working capital | $27.42 million | $32.62 million |
| Short-term borrowings | $2.44 million | $2.48 million |
Revenue fell 28.9%. Cost of revenue declined less, so gross margin contracted by 11.4 percentage points. General and administrative expense was about $4.55 million including a $395,506 intangible-asset impairment; selling expense was $1.17 million. The year-end current-asset and current-liability figures imply a current ratio of approximately 8.4, although cash was down year over year. The company reported a $2.87 million gain from remeasuring warrant liabilities, which materially supported reported net income despite the operating loss. The difference between consolidated net income and income attributable to Dehaier reflects a loss allocated to non-controlling interests.
Operating cash flow improved to $4.14 million, helped substantially by a $5.24 million decrease in prepayments and other current assets. Investing outflows rose sharply, including $7.03 million for capital expenditures and other additions and $4.17 million for intangible assets. The company raised approximately $6.07 million net from a February 2014 share offering. Total liabilities were $4.23 million, including $2.44 million of short-term borrowings; the bank credit was secured by a related-party building and guaranteed by BDL and a company officer.
Material changes versus prior year
- Revenue declined for a second consecutive year, from $21.37 million in 2012 to $16.86 million in 2013 and $11.99 million in 2014.
- The company reduced traditional medical-device activity and redirected resources toward sleep respiratory and mobile-medicine offerings. Medical-device revenue was $10.30 million, down from $14.82 million; the filing’s product-line table reports respiratory and oxygen homecare revenue of $53,755 versus $2.03 million in 2013, and mobile-medicine revenue of $1.63 million.
- Operating results swung from $3.51 million of operating income to a $2.11 million operating loss, as lower revenue and substantially higher administrative and development costs outweighed expense reductions.
- Research and development spending rose to $615,334 from $484,770. The company recorded a $395,506 impairment of software-copyright assets and a $541,944 inventory-obsolescence provision in cash-flow adjustments.
- Cash declined by $865,182. Shareholders’ equity increased, in part reflecting the share offering and share-based awards; issued and outstanding shares rose to 5,808,675 at year-end from 4,668,000.
Outlook, commentary and risks
Management said it expected sleep respiratory to drive meaningful overall revenue growth in 2015 and planned further investment in products, R&D, sales and market development. It cited delivery and installation of sleep-respiratory systems at more than 60 hospitals and private medical examination centers by the end of March 2015. No quantified revenue or earnings guidance was provided. Management stated that available working capital should support at least 12 months of current operations, while noting expansion could require operating cash, debt or equity financing.
- Key risks include continued market and pricing pressure, dependence on distributors and a concentrated set of products, customers and suppliers, and execution risk in the early-stage sleep-respiratory and mobile-medicine businesses.
- Regulatory approvals and renewals are required for medical devices in China. The filing identifies product registrations nearing expiry and says the Timesco laryngoscope renewal was pending.
- China-related risks include currency conversion and remittance restrictions, changing regulation and tax treatment, and uncertainty in the PRC legal environment. The company reported no currency hedging and said RMB fluctuations reduced 2014 operating income by $31,000.
- The company reported that disclosure controls were not effective and identified lack of full-time accounting personnel with U.S. GAAP experience as a material weakness in internal control over financial reporting. Management outlined training, review and hiring plans. The auditor gave an unqualified opinion on the financial statements but did not audit internal controls.
- Related-party exposure included $1.14 million of purchases from a company partially owned by the CEO and $1.50 million advanced to that related party for equipment purchases. The filing also describes the related-party building securing bank borrowings.
- The filing says the company had not established statutory reserves at BDL despite discussing PRC reserve requirements; it notes potential regulatory consequences and possible constraints on distributions.
Important facts for investors to verify
- Confirm the correct issuer and period: this source is Dehaier’s FY 2014 Form 20-F, not a Newegg 2014 Q4 filing.
- Reconcile the product-line revenue table with management’s statements that sleep respiratory represented 10% of revenue and mobile medicine about 14%; those descriptions do not clearly match the table’s reported categories and amounts.
- Check the reported $2.87 million warrant fair-value gain and its effect on net income, EPS and operating cash-flow reconciliation.
- Assess collection and asset quality: net accounts receivable were $11.83 million, the doubtful-account allowance rose to $1.60 million, and inventory increased to $6.20 million with a substantially higher obsolescence reserve.
- Verify execution and returns on the large investment in sleep-respiratory equipment, software and intellectual property, including related-party deposits and the reported impairment.
- Monitor near-term loan maturities, collateral and guarantees, cash conversion, and management’s progress in addressing the disclosed internal-control material weakness.